Categories
MedTech Pharma Marketing

What is Omnichannel Marketing in Pharma & Medtech? Complete Definition Guide 2025

FAQ #1: What is Omnichannel Marketing in Pharma and Medtech?

Omnichannel marketing in pharmaceutical and medical device industries is a customer-centric approach that integrates multiple communication channels to create seamless, personalized experiences for healthcare professionals (HCPs), patients, and other stakeholders. Unlike traditional multichannel marketing where channels operate independently, omnichannel marketing connects digital and physical touchpoints into a unified ecosystem that recognizes users across their entire healthcare journey.1

The core principle involves using interconnected channels that work together to enhance customer experience and engagement. Each channel is optimized and working in harmony to provide consistent messaging while allowing for channel-specific customization. This includes everything from email marketing and social media to in-person sales visits, webinars, and mobile applications.2

Key characteristics that distinguish omnichannel from multichannel approaches include:

  • Unified customer data across all touchpoints
  • Consistent brand messaging with channel-appropriate customization
  • Seamless transitions between different interaction points
  • Personalized content based on individual customer profiles
  • Cross-channel insights that inform future interactions

For medical device companies, this means creating cohesive messaging across various platforms to boost engagement and conversions. The approach enables companies to reach healthcare professionals wherever they are, regardless of their preferred communication channel, while maintaining consistency in brand experience.3

Studies show that omnichannel personalization can halve acquisition costs, increase marketing budget efficiency by 10% to 30%, and increase revenue by 5% to 15%. This significant impact explains why 98% of pharmaceutical executives emphasize the importance of implementing an omnichannel strategy for their organizations.4,5,6

This is a part of The Complete Guide to Omnichannel Marketing in Pharma and Medtech series.

This content has been enhanced with GenAI tools.

Read other series:

Scaling MedTech: From Product to Market

SaMD Europe Launch Guide

Categories
MedTech Pharma Marketing

Navigating MLR with AI

What is MLR and why does it matter in pharma and MedTech marketing?

MLR stands for Medical, Legal and Regulatory review. It is a mandatory, cross-functional process that ensures that all promotional, educational and informational materials are:

  • accurate and balanced
  • scientifically substantiated
  • compliant with global and local regulations

In highly regulated industries like pharmaceuticals and MedTech, MLR approval is a critical checkpoint before any HCP-facing or public content goes live. Failure to follow MLR requirements can result in:

  • Regulatory penalties
  • Product delistings
  • Legal liabilities
  • Damaged reputation

As content volume increases with the rise of omnichannel and AI-generated materials traditional MLR workflows can become a bottleneck unless modernized.

How can AI improve MLR workflows?

AI supports MLR processes in three major ways:

1. Content Pre-Screening

AI tools can scan drafts to:

  • Flag non-compliant language
  • Identify missing references or claims
  • Highlight risky phrasing (e.g., off-label implications)

This allows compliance teams to focus human review where it’s most needed, accelerating the overall review cycle.

2. Co-Pilots for MLR Teams

AI-powered assistants can:

  • Suggest alternative compliant language
  • Autofill references from approved claim libraries
  • Surface similar approved content as templates

These tools significantly reduce manual effort, especially during content revisions.

3. Approval of Modular Content

The modular content model breaks content into pre-approved blocks. AI can then:

  • Assemble high-volume personalized content on demand
  • Guarantee compliance by combining only validated modules
  • Eliminate hallucination risk (a common issue with generative AI)

This method not only accelerates content production but also reduces MLR review time by up to 60%.

How does AI integrate into the MLR approval chain?

Phase AI Role Benefit

PhaseAI RoleBenefit
Pre-MLRDrafting, tone adjustment, auto-translationFaster initial content creation
MLR ReviewPre-screening, red-flagging issues, checking against literature referencesPrioritizes human review efficiently
Post-MLR DeploymentMatching with HCP profiles, tagging usageTracks content reuse & optimization

The AI’s involvement must be transparent, traceable, and auditable, ensuring compliance with internal SOPs and external guidelines.

What are the risks and limitations of AI in MLR?

While AI accelerates MLR processes, there are important caveats:

  • Hallucinations: Generative AI may invent plausible-sounding but false claims. Limiting AI to assembly of approved blocks solves this.
  • Regulatory uncertainty: Global health authorities (e.g., FDA, EMA) have not yet fully defined how AI-assisted content creation fits within promotional regulations.
  • Tool validation: Any AI tool used must undergo proper validation, risk assessment, and documentation — especially in GxP environments.

Best practices for AI-driven MLR transformation

  • Separate AI use by stage
    • Use generative AI only before MLR to assist with content ideation or rephrasing.
    • Use only pre-approved content for AI assembly after MLR.
  •  Invest in modular content strategy
    • Pre-approve reusable content blocks to scale faster without repeated review cycles.
  •  Enable “compliance by design”
    • Integrate claim libraries, brand guardrails, and reference checkers directly into content tools.
  • Improve the supply chain, not just speed
    • Faster content creation is meaningless without scalable MLR capacity.
  •  Partner with experienced vendors
    • Choose platforms and agencies that specialize in life sciences compliance and can demonstrate audit readiness.

Summary

Modern MLR is no longer just a gatekeeper. MLR process is a strategic enabler of fast, scalable, and compliant pharma marketing. When powered responsibly by AI, it can cut approval cycles from weeks to days, support omnichannel campaigns, and free up expert reviewers for higher-value tasks.

The future of compliant content in life sciences is modular, AI-assisted, and human-supervised — and it’s already underway.

This text has been enganced with GenAI tools.

Categories
MedTech Pharma Marketing

Top Use Cases of AI in Pharma & MedTech

What are the main forms of generative AI being leveraged in pharma marketing?

Generative AI can be categorized into three general uses:

  • Content Generators: These produce texts, images, and video rapidly, and can also refine content by changing tone, simplifying information, or fine-tuning messages for specific audience segments.
  • Answer Engines: These are new forms of ‘search’ that generate direct answers (text, images, video) rather than just providing links. They can be used to extract insights from market research reports or summarize clinical studies.
  • Agents (Large Action Models – LAMs): These forms of AI act to achieve specific goals without specific instructions or human oversight. For example, an AI agent could review keynote Q&As and social media reactions to assess the medical community’s response to a drug launch. These are considered the most controversial due to their autonomous nature.

What are the primary use cases for AI in pharma and MedTech marketing?

There are four broad categories of AI use cases in pharma and MedTech marketing:

  1. Strategic Insights Generation: AI can analyze vast amounts of both structured (e.g., CRM data) and unstructured data (e.g., government policy documents, articles on HCP preferences) to generate actionable insights and trends. This can improve understanding by up to 30%. However, caution is advised as AI can produce plausible but incorrect results (“AI hallucination”).
  2. Marketing Content Generation: AI is crucial for omnichannel strategies that require high content volume for personalization. It can rapidly generate various content formats (texts, images, video, audio) and reduce content creation costs by 30-50%.
  3. MLR Acceleration (Medical, Legal, Regulatory Review): AI can modernize labor-intensive MLR processes, which typically take 21 to 56 days for approval. AI tools can pre-screen materials, flagging problematic content for detailed review and fast-tracking compliant assets. AI co-pilots can also assist MLR staff with referencing claims and rephrasing options, potentially accelerating content approvals two to three times.
  4. Field Force Enablement: AI benefits customer-facing staff like sales teams and Medical Science Liaisons (MSLs) by improving training, account planning, and content delivery. AI can provide immediate access to drug information, offer coaching for specific situations, and integrate with CRM to help reps prioritize accounts and personalize HCP engagements based on “next best” message or format recommendations.
Categories
Pharma Marketing

Understanding AI in Pharma Marketing

What is Artificial Intelligence (AI) in a pharma commercial context?

In a pharma commercial context, AI primarily refers to generative AI, which differs from traditional “classical AI” or machine learning.

  • Classical AI / Machine Learning models perform specific tasks, like analyzing data for predictions or identifying patient groups, using very specific datasets.
  • Generative AI works with a foundational, large language model (LLM) trained on vast amounts of data, enabling it to be applied to many different problems. Its key characteristics include:
    •   Basic competences applicable to various problems.
    •   Ability to learn from structured and unstructured data.
    •   Generation of multiple outputs such as texts, images, speech, video, and designs.
    •     An intuitive, conversational user interface.

In pharma, generative AI is used for activities like writing marketing materials, generating webinars, building image and video libraries, spotting segmentation opportunities, and speeding up marketing processes. It is projected to grow faster in healthcare than any other industry, potentially generating between $60 billion and $110 billion a year in economic value for the pharma and MedTech industries, with most value going to commercial operations.

Categories
MedTech Pharma Marketing

Multichannel vs Omnichannel in Pharma Marketing

What is the difference between multichannel and omnichannel marketing in pharma and MedTech?

Multichannel marketing uses multiple independent channels (like television, social media, email, websites) to communicate with customers. In this approach, channels often operate as silos, repeating the same message, with the focus remaining on the product rather than the user. It lacks a connecting node between channels.


Omnichannel marketing also engages multiple channels, but they are all integrated and coordinated to provide a unified, seamless, and personalized experience for the customer, who is placed at the center of the marketing funnel. This approach ensures that information is available precisely when needed, encourages deeper content exploration, and reinforces messages across touchpoints, ultimately improving engagement and fostering trust.

According to McKinsey, correctly implemented omnichannel models can lead to 5-10% revenue growth and 10-20% marketing efficiencies and cost savings for pharma companies.

Categories
Digital Health MedTech

Why SaMD Launches Fail in Europe

Common Pitfalls

  1. Vague intended use leading to misclassification
  2. No QMS or weak cybersecurity
  3. Poor clinical evidence strategy
  4. Failure to engage clinicians or users

Fixes:

  • Start regulatory early
  • Build real clinical value
  • Design with adoption in mind

Learn more at Scaling MedTech: From Product to Market

This post is part of SaMD Europe Launch Guide.

This content has been enhanced by GenAI tools.

Categories
Digital Health MedTech

Investment Trends in European Digital Health

Where Capital Flows

Investors favor:

  • AI-powered platforms
  • Value-based care tools
  • Female health (menopause, hormones)

Valuation Benchmarks:

  • 4–6x revenue for most healthtech
  • 6–8x for AI/diagnostics
  • 10–14x EV/EBITDA for EBITDA-positive firms

Learn more at Scaling MedTech: From Product to Market

This post is part of SaMD Europe Launch Guide.

This content has been enhanced by GenAI tools.

Categories
Digital Health MedTech

Post-Market Surveillance for SaMD

Staying Compliant Post-Launch

Post-market surveillance (PMS) is required for all devices.

Requirements:

  • Plan for data collection
  • Trend analysis and signal detection
  • Regular updates to clinical files
  • Vigilance reporting (e.g. EUDAMED)

For Class IIa+, submit PSUR every 1–2 years.

This post is part of SaMD Europe Launch Guide.

This content has been enhanced by GenAI tools.

Categories
Digital Health MedTech

SaMD Market Access & Reimbursement in Europe

CE Mark ≠ Reimbursement

Each EU country has its own reimbursement process.

Highlights:

– Germany (DiGA): Fast track, 12-month provisional access

– France: Multiple programs (ETAPES, PECAN)

– UK: NICE approval + local commissioning (ICBs)

Evidence needs differ, it can be Randomized Controlled Trials (RCTs) or real-world evidence depending on system.

Learn more on Scaling MedTech: From Product to Market

This post is part of SaMD Europe Launch Guide.

This content has been enhanced by GenAI tools.

Categories
Digital Health MedTech

Clinical Evidence for SaMD in the EU

MDR Requirements

SaMD must show:

  • Clinical association (medical logic)
  • Analytical validity (correct processing)
  • Clinical validation (real-world benefit)

Documentation:

  1. Clinical Evaluation Plan (CEP) = how you’ll gather evidence
  2. Clinical Evaluation Report (CER) = full evaluation
  3. Post-Market Clinical Follow-up (PMCF) = follow-up after launch

Use real-world evidence, literature, or clinical studies.

This post is part of SaMD Europe Launch Guide.

This content has been enhanced by GenAI tools.